Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SanBio Co Ltd    4592   JP3336750009

SANBIO CO LTD (4592)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

SanBio : US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor Deficit from Ischemic Stroke Was Addressed at an Event Held by California Institute for Regenerative Medicine (CIRM)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/15/2018 | 04:31am CEST

The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke conducted by the SanBio group was addressed at an event held by California Institute for Regenerative Medicine (CIRM) on May 31, 2018.

The recording of the event is available for view at https://www.facebook.com/CaliforniaInstituteForRegenerativeMedicine/

SanBio, Inc. and SanBio Co., Ltd.

SanBio group is engaged in the regenerative medicine business spanning research, development, manufacture, and sales of regenerative medicines. In regards to its propriety regenerative medicine product SB623, SanBio is conducting a phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US together with its development partner in the US and Canada, Sumitomo Dainippon Pharma Co., Ltd. On its own, SanBio is conducting a global phase 2 clinical trial of SB623 targeting chronic motor deficit from TBI in Japan and the US. Headquartered in Tokyo, SanBio has its main R&D base in Mountain View, California in the US.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANBIO CO LTD
06/15SANBIO : US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chroni..
BU
06/11SANBIO CO LTD : quaterly earnings release
05/25SANBIO : Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer a..
BU
04/02SANBIO : Update on Development Progress of Regenerative Cell Medicine SB623
BU
01/04SANBIO : Primary Researcher Receives 2017 Smithsonian American Ingenuity Award
BU
2017SANBIO CO LTD : quaterly earnings release
2017SANBIO : Names Mohammad El-Kalay New Technical Operations SVP
BU
2017SANBIO CO LTD : half-yearly earnings release
2017SANBIO : $150 000 shot in the arm for STEM
AQ
2017SANBIO : South Africa finals of FemBioBiz Acceleration Competition today
AQ
More news
News from SeekingAlpha
2016Picking Winners Still Possible In Q1 
Financials ( JPY)
Sales 2019 3 044 M
EBIT 2019 -
Net income 2019 -463 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 252,82
Capi. / Sales 2019 49,3x
Capi. / Sales 2020 39,1x
Capitalization 150 B
Chart SANBIO CO LTD
Duration : Period :
SanBio Co Ltd Technical Analysis Chart | 4592 | JP3336750009 | 4-Traders
Technical analysis trends SANBIO CO LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 3 084  JPY
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Keita Mori President & Representative Director
Toru Kawanishi Chairman
Damien Bates Chief Medical Officer & Head-Development
Noboru Kotani Independent Outside Director
Mohammad A. El-Kalay Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SANBIO CO LTD-8.21%1 355
GILEAD SCIENCES-0.98%92 241
VERTEX PHARMACEUTICALS3.10%39 371
REGENERON PHARMACEUTICALS-13.00%34 653
SAREPTA THERAPEUTICS INC176.22%9 432
NEUROCRINE BIOSCIENCES, INC.32.39%9 234